Idorsia Ltd (IDIA) AI Stock Analysis

Compare

1 Followers

Top Page

Idorsia Ltd

(IDIA)

Rating:51Neutral

Price Target:

CHF2.00

▲(21.21%Upside)

Idorsia Ltd's overall stock score is primarily impacted by its poor financial performance, with ongoing profitability and cash flow challenges. The technical analysis shows positive momentum, but the overbought indicators suggest caution. Valuation concerns due to negative earnings also weigh on the score.

Idorsia Ltd (IDIA) vs. iShares MSCI Switzerland ETF (EWL)

Market Cap

CHF382.17M

Dividend YieldN/A

Average Volume (3M)964.86K

Price to Earnings (P/E)―

Beta (1Y)2.79

Revenue Growth11.61%

EPS Growth-356.20%

CountryCH

Employees636

SectorHealthcare

Sector Strength41

IndustryBiotechnology

Share Statistics

EPS (TTM)-0.13

Shares Outstanding225,852,700

10 Day Avg. Volume1,269,969

30 Day Avg. Volume964,858

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)-0.24

Price to Sales (P/S)0.00

P/FCF Ratio-0.51

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

CHF2.20

Price Target Upside33.33% Upside

Rating ConsensusHold

Number of Analyst Covering1

Idorsia Ltd Business Overview & Revenue Model

Company DescriptionIdorsia Ltd (IDIA) is a biopharmaceutical company based in Switzerland, focused on discovering, developing, and commercializing innovative small molecules to address unmet medical needs. The company operates primarily in the pharmaceutical sector, with a strong emphasis on research and development. Idorsia's core products include treatments for insomnia, hypertension, and other serious conditions, leveraging its robust pipeline of drug candidates in various stages of clinical development.

How the Company Makes MoneyIdorsia Ltd generates revenue primarily through the development and commercialization of its pharmaceutical products. The company makes money by bringing its proprietary drugs to market, which involves obtaining regulatory approvals and launching these products globally. Idorsia also enters into strategic partnerships and licensing agreements with other pharmaceutical companies, which can provide upfront payments, milestone payments, and royalties based on product sales. Additionally, the company may receive funding and support from collaborations in research and development efforts, further contributing to its revenue streams. These partnerships help Idorsia to expand its market reach and share the risks and costs associated with drug development.

Idorsia Ltd Earnings Call Summary

Earnings Call Date:Apr 30, 2025

(Q4-2024)

% Change Since: 39.83%|

Next Earnings Date:Jul 30, 2025

Earnings Call Sentiment Neutral

The earnings call conveyed a balanced sentiment. While Idorsia faced challenges, such as the failed licensing agreement for aprocitentan and financial pressures leading to cost reductions, it also highlighted significant achievements. These included QUVIVIQ's market expansion and sales growth in Europe, Canada, and the US, and strategic financial maneuvers that ensured stability and future funding. Overall, the company is maneuvering through its challenges with a focus on growth and financial stability.

Q4-2024 Updates

Positive Updates

QUVIVIQ European and Canadian Market Expansion

QUVIVIQ is now available in nine countries across Europe and Canada, achieving CHF 32 million in net sales in 2024. Sales have shown a steady increase, with significant acceleration in Q4 driven by Germany and France.

US Sales Growth Despite Reduced Investments

QUVIVIQ's US sales grew to over CHF 28 million in 2024 despite a reduction in marketing and selling investments, showing steady growth.

Financial Stability Achieved Through Strategic Measures

Idorsia reduced its R&D commitment by US$100 million and restructured its convertible bonds, securing a new money facility of CHF 150 million, ensuring funds well into 2026.

Aprocitentan Approval and Launch Plans

TRYVIO (aprocitentan) received approval in the US and EU, with preparations for a focused launch in the US ongoing despite previous licensing setbacks.

Negative Updates

Failed Aprocitentan Licensing Agreement

The out-licensing agreement for aprocitentan could not be closed due to the undisclosed party's refusal to pay an exclusivity fee, necessitating alternative partnership strategies.

Financial Challenges and Cost Reductions

Despite strategic financial maneuvers, Idorsia faced significant financial pressures, including a non-GAAP operating loss of CHF 308 million.

Company Guidance

During the call, Idorsia provided guidance for 2025, with the expectation of reaching CHF 110 million in sales for QUVIVIQ, driven by strong performance in the EUCAN region. The company anticipates a non-GAAP EBIT loss of CHF 215 million, a significant improvement from previous years, thanks to cost reductions and a restructuring of their convertible bonds. This includes a CHF 100 million reduction in R&D commitments and a new CHF 150 million funding facility. The US GAAP result is projected at CHF 155 million, incorporating these financial maneuvers. Idorsia remains focused on securing partnerships for their pipeline assets, particularly aprocitentan, to further stabilize and extend their financial runway.

Idorsia Ltd Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Breakdown
Income Statement		Total Revenue
70.62M	152.39M	97.10M	35.35M	71.76M	23.82M
	Gross Profit
38.78M	145.24M	90.84M	17.32M	-309.32M	-414.71M
	EBIT
-385.38M	-543.05M	-802.96M	-613.00M	-410.58M	-482.42M
	EBITDA
-246.30M	-254.55M	-783.09M	-588.84M	-420.64M	-457.34M
	Net Income Common Stockholders
-296.39M	-297.92M	-827.90M	-634.60M	-445.12M	-494.65M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
811.85M	157.82M	476.32M	1.04B	1.01B	743.07M
	Total Assets
1.36B	500.00M	904.18M	1.48B	1.44B	1.00B
	Total Debt
623.92M	1.20B	1.23B	1.16B	637.99M	631.32M
	Net Debt
-93.72M	1.06B	1.08B	1.06B	497.18M	368.32M
	Total Liabilities
805.18M	1.47B	1.57B	1.38B	849.88M	839.85M
	Stockholders Equity
562.99M	-968.72M	-660.96M	104.20M	585.48M	172.44M
Cash Flow		Free Cash Flow
-444.30M	-638.69M	-886.17M	-620.83M	-373.95M	-481.03M
	Operating Cash Flow
-427.18M	-629.30M	-859.11M	-589.89M	-364.67M	-462.04M
	Investing Cash Flow
321.40M	632.61M	743.90M	-53.26M	-607.13M	-74.81M
	Financing Cash Flow
-80.00K	-197.00K	162.31M	604.15M	850.08M	1.33M

Idorsia Ltd Technical Analysis

Technical Analysis Sentiment

Positive

Last Price1.65

Price Trends

50DMA

1.28

Positive

100DMA

1.09

Positive

200DMA

1.17

Positive

Market Momentum

MACD

0.16

Negative

RSI

86.24

Negative

STOCH

84.27

Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:IDIA, the sentiment is Positive. The current price of 1.65 is above the 20-day moving average (MA) of 1.51, above the 50-day MA of 1.28, and above the 200-day MA of 1.17, indicating a bullish trend. The MACD of 0.16 indicates Negative momentum. The RSI at 86.24 is Negative, neither overbought nor oversold. The STOCH value of 84.27 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:IDIA.

Idorsia Ltd Peers Comparison

Overall Rating

UnderperformOutperform

Sector (54)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BSLN	75 Outperform	CHF564.34M	7.68		―	32.30%	631.04%
NWRN	68 Neutral	$146.11M	10.37		―	450.19%	―
Sector *	54 Neutral	$5.28B	3.29	-45.38%	2.80%	16.77%	-0.08%
IDIA	51 Neutral	CHF382.17M	―		―	11.61%	-356.20%
MOLN	47 Neutral	CHF122.34M	―	-40.40%	―	-66.82%	4.14%
SANN	44 Neutral	$127.29M	2.58	-93.91%	―	-62.17%	-166.33%

* Healthcare Sector Average

Performance Comparison

CH:IDIA

Idorsia Ltd

2.00

-0.28

-12.28%

CH:MOLN

Molecular Partners AG

2.95

-0.79

-21.23%

CH:BSLN

Basilea Pharmaceutica

49.20

7.00

16.59%

CH:NWRN

Newron Pharmaceuticals SpA

7.32

-2.58

-26.06%

CH:SANN

Santhera Pharmaceuticals Holding

13.14

3.54

36.88%

Glossary

OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.

NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.

UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.